Global Pediatric Brain Tumors Scope 2025, Forecast To 2034
26 Mar, 2025
What are the Historical Developments and Current Growth Metrics of the Pediatric Brain Tumors Market?
The pediatric brain tumors market has seen considerable growth due to a variety of factors.
• In recent times, we've seen significant growth in the pediatric brain tumor market size. It is predicted to grow from $1.4 billion in 2024 to $1.5 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.1%.
A number of factors have contributed to the growth during the historic period, including an ascending trend in pediatric brain tumor cases, emerging economies, an uptick in research and development investments, and a rising demand for diagnostic technology. Furthermore, instances of pediatric tumors are on the rise on a global scale.
What Does Future Hold for The Pediatric Brain Tumors Market By 2029?
The pediatric brain tumors market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for pediatric brain tumors is projected to witness robust growth in the coming years. By 2029, it's predicted to expand to $1.83 billion with a compound annual growth rate (CAGR) of 5.1%.
This expected growth throughout the prediction period can be credited to several factors such as precision medicine, molecular profiling, targeted therapy, the improvement in healthcare infrastructure, and the broadening of insurance coverage. Notable trends in the prediction phase encompass the enhancements seen in technologies used in magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scanning, the application of genetic and molecular profiling, the creation of targeted therapies, the inception of immunotherapies, and the emergence of minimally invasive surgical procedures.
What Are The Primary Growth Drivers In The Pediatric Brain Tumors Market?
The pediatric brain tumors market is anticipated to expand due to the increasing necessity for personalized medicine. Personalized medicine refers to a medical approach tailored to an individual's genetic composition, lifestyle, and exclusive health needs. Advanced genetic research, enhanced diagnostic tools, and the possibility of more efficient, targeted treatments have driven up the need for personalized medicine. By adjusting treatments according to the specific tumor type, mutation, and response of the child, personalized medicine enables more efficient targeted therapies that cause less harm to healthy tissue, bettering outcomes and minimizing side effects. For example, in February 2024, the Personalized Medicine Coalition, a healthcare organization based in the U.S, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from six in 2022. Hence, the rising demand for personalized medicine is fueling the expansion of the pediatric brain tumor market.
What Is The Segmentation Of The Global Pediatric Brain Tumors Market?
The pediatric brain tumors market covered in this report is segmented –
1) By Type: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma Or Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors
2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
3) By Diagnosis Method: Imaging Techniques, Biopsy, Neurological Exam, Lumbar Puncture
4) By Age Group: Infants, Toddlers, Children, Adolescents
5) By Application: Hospitals And Clinics, Medical Research Centers, Academic Institutes, Other Applications
Subsegments:
1) By Gliomas: Low-Grade Gliomas, High-Grade Gliomas
2) By Mixed Neuronal-Glial Tumors: Gangliogliomas, Dysembryoplastic Neuroepithelial Tumors (DNET)
3) By Embryonal Tumors: Medulloblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Primitive Neuroectodermal Tumors (PNET)
4) By Choroid Plexus Papilloma or Carcinoma: Choroid Plexus Papilloma, Choroid Plexus Carcinoma
5) By Tumors Arising from Non-Neuroepithelial Tissue: Rhabdomyosarcoma, Ewing's Sarcoma
6) By Meningeal Tumors: Meningiomas, Hemangiopericytomas
What New Trends Are Influencing The Pediatric Brain Tumors Market?
Significant organizations in the pediatric brain tumors sector are emphasizing the development of advanced treatments like type II RAF inhibitors to augment targeted treatments and enhance patient outcomes. These inhibitors are targeted therapies focused on inhibiting RAF kinases, especially those with mutations propelling tumor growth. In particular, these inhibitors are engineered to target abnormal RAF protein forms discovered in specific pediatric low-grade glioma (pLGG) subtypes, effectively inhibiting the defective signaling pathways encouraging tumor cell expansion and survival. For instance, Day One Biopharmaceuticals, a biotech firm based in the U.S., declared in April 2024 that it had received accelerated approval from the U.S. Food and Drug Administration (FDA) for OJEMDA (tovorafenib), a drug intended to treat relapsed or refractory pLGG in patients at least 6 months old with specific BRAF modifications. This marked OJEMDA as the first therapy to be FDA-approved targeting BRAF fusions or mutations in these patients. The authorization is founded on a reported overall response rate of 51% from the FIREFLY-1 clinical study, which evaluated the treatment's effectiveness. The drug is specifically directed toward children with brain tumors unresponsive to prior therapies.
Who Are the Key Players In The Pediatric Brain Tumors Market?
Major companies operating in the pediatric brain tumors market are:
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Roche Holding AG
• Takeda Pharmaceutical Company
• UCLA Health
• Ipsen Pharma
• Novocure
• Blueprint Medicines
• Karyopharm Therapeutics Inc.
• Renaissance Pharma
• Servier Laboratories
• Matica Biotechnology
• Curis Inc.
• Oncoheroes Biosciences
• Treovir Inc.
• Plus Therapeutics Inc.
• Stemline Therapeutics Inc.
• BrainChild Bio Inc.
• Seattle Children's Therapeutics
What Are The Regional Insights Into The Pediatric Brain Tumors Market?
North America was the largest region in the pediatric brain tumors market in 2024. The regions covered in the pediatric brain tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.